Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Osteosarcoma 2Mucositis 1Lymphoma, Large B-Cell, Diffuse 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cyclophosphamide 14fludarabine 10fludarabine phosphate 8Whole-Body Irradiation 7thymoglobulin 5Thiotepa 5Tacrolimus 5Stem Cell Transplantation 5Standard of Care 5Practice Guidelines as Topic 5Nivolumab 5Granulocyte Colony-Stimulating Factor 5Busulfan 5Azacitidine 5venetoclax 4Radiotherapy 4Mycophenolic Acid 4Methotrexate 4Melphalan 4Filgrastim 4Cytarabine 4Antilymphocyte Serum 4Rituximab 3Mesna 3Leucovorin 3Dexamethasone 3Calcium Dobesilate 3Alemtuzumab 3ruxolitinib 2ceritinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hematologic Neoplasms × glucarpidase × Clear all
NCT00424645 2012-12-06

Voraxaze for Delayed Methotrexate Clearance

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 2 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡